{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:59:48Z","timestamp":1791604788377,"version":"4.3.4"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejim.2019.07.022","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T08:04:12Z","timestamp":1564473852000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Cardiac amyloidosis: An underdiagnosed\/underappreciated disease"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-4745","authenticated-orcid":false,"given":"Antonis S.","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis A.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora A.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Melita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2019.07.022_bb0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0010","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11886-015-0653-1","article-title":"Emerging advances in the management of cardiac amyloidosis","volume":"17","author":"Vranian","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ejim.2019.07.022_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pcad.2009.11.007","article-title":"Amyloid heart disease","volume":"52","author":"Falk","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2019.07.022_bb0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2019.07.022_bb0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2019.07.022_bb0035","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCRESAHA.117.310643","article-title":"Amyloid cardiomyopathy: disease on the rise","volume":"120","author":"Liao","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2019.07.022_bb0040","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types","volume":"33","author":"Nativi-Nicolau","year":"2018","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11886-017-0911-5","article-title":"Transthyretin cardiac amyloidosis","volume":"19","author":"Mankad","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ejim.2019.07.022_bb0050","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/eurheartj\/ehz057","article-title":"Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis","volume":"40","author":"van den Berg","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0055","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2019.07.022_bb0065","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2141.2001.02999.x","article-title":"Amyloidosis: a convoluted story","volume":"114","author":"Kyle","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0070","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0075","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0090","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2019.07.022_bb0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ejim.2019.07.022_bb0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0735-1097(84)80436-2","article-title":"Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities","volume":"3","author":"Falk","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0105","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0110","doi-asserted-by":"crossref","first-page":"838","DOI":"10.7326\/0003-4819-131-11-199912070-00007","article-title":"Systemic amyloidosis presenting with angina pectoris","volume":"131","author":"Al Suwaidi","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0115","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0120","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0125","first-page":"e78","article-title":"Cerebral embolism due to atrial myopathy in a cardiac amyloidosis patient diagnosed by cardiac magnetic resonance imaging","volume":"7","author":"Shinoda","year":"2013","journal-title":"J Cardiol Cases"},{"key":"10.1016\/j.ejim.2019.07.022_bb0130","doi-asserted-by":"crossref","first-page":"W394","DOI":"10.2214\/AJR.09.3721","article-title":"MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy","volume":"195","author":"Di Bella","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0135","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0140","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2017.09.001","article-title":"Ocular manifestations of familial transthyretin amyloidosis","volume":"183","author":"Reynolds","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0145","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejim.2019.07.022_bb0150","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2019.07.022_bb0155","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1111\/echo.13355","article-title":"Alterations in regional myocardial deformation assessed by strain imaging in cardiac amyloidosis","volume":"33","author":"Lo","year":"2016","journal-title":"Echocardiography"},{"key":"10.1016\/j.ejim.2019.07.022_bb0160","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0165","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.15252\/emmm.201404190","article-title":"Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity","volume":"6","author":"Guan","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0170","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-125-6-199609150-00009","article-title":"Resolution of heart failure in patients with AL amyloidosis","volume":"125","author":"Dubrey","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants, 2003","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0180","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0185","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of Transthyretin cardiac amyloidosis: THAOS (Transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0190","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0195","first-page":"1074","article-title":"Incidence of amyloidosis over 3 years: the AMYPRO study","volume":"26","author":"Magy-Bertrand","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0200","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/PAS.0b013e3181788566","article-title":"Prevalence of germline mutations in the TTR gene in a consecutive series of surgical pathology specimens with ATTR amyloid","volume":"33","author":"Eriksson","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0210","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00428-010-0909-5","article-title":"Amyloid in endomyocardial biopsies","volume":"456","author":"Kieninger","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ejim.2019.07.022_bb0215","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0220","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0225","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2019.07.022_bb0230","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonzalez-Lopez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0235","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0240","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin amyloidosis outcomes survey (THAOS)","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0245","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2019.07.022_bb0250","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/eurheartj\/ehy697","article-title":"Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?","volume":"40","author":"Falk","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0255","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0260","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2018.01.016","article-title":"Spectrum of restrictive and infiltrative cardiomyopathies: part 1 of a 2-part series","volume":"71","author":"Pereira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0265","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0270","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0275","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12265-015-9628-2","article-title":"Optimization of serum immunoglobulin free light chain analysis for subclassification of cardiac amyloidosis","volume":"8","author":"Halushka","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.ejim.2019.07.022_bb0280","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.mayocp.2017.09.016","article-title":"Prevalence of monoclonal gammopathy in wild-type transthyretin amyloidosis","volume":"92","author":"Geller","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2019.07.022_bb0285","first-page":"136","article-title":"Prognostic value of high-sensitivity cardiac troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis","volume":"11","author":"Qian","year":"2014","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/13506120903421538","article-title":"Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis","volume":"16","author":"Lehrke","year":"2009","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173086","article-title":"Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - report from the transthyretin amyloidosis outcome survey (THAOS)","volume":"12","author":"Kristen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2019.07.022_bb0300","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0305","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/13506129.2010.483118","article-title":"Serum transthyretin levels in Swedish TTR V30M carriers","volume":"17","author":"Buxbaum","year":"2010","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0310","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13506129.2017.1295371","article-title":"Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis","volume":"24","author":"Arvanitis","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","article-title":"Identification of Transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model","volume":"2","author":"Arvanitis","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0320","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejim.2019.07.022_bb0325","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10741-019-09776-3","article-title":"Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement","volume":"24","author":"Rigopoulos","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2019.07.022_bb0330","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation","volume":"106","author":"Rocken","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0335","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0046-8177(93)90239-D","article-title":"Isolated atrial amyloidosis: a clinicopathologic study indicating increased prevalence in chronic heart disease","volume":"24","author":"Looi","year":"1993","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0340","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ehj.2004.04.007","article-title":"Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation","volume":"25","author":"Leone","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0345","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10741-014-9466-3","article-title":"Echocardiography in cardiac amyloidosis","volume":"20","author":"Falk","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2019.07.022_bb0350","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/echo.13278","article-title":"Longitudinal strain of left ventricular basal segments and E\/e' ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study","volume":"33","author":"Schiano-Lomoriello","year":"2016","journal-title":"Echocardiography"},{"key":"10.1016\/j.ejim.2019.07.022_bb0355","first-page":"635","article-title":"Relative apical sparing of longitudinal strain in speckle-tracking echocardiography: a sensitive and specific finding in cardiac amyloidosis","volume":"26","author":"Gil","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2019.07.022_bb0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40001-016-0216-y","article-title":"Longitudinal strain bull's eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy","volume":"21","author":"Liu","year":"2016","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ejim.2019.07.022_bb0365","first-page":"176","article-title":"Segmental and global longitudinal strain and strain rate based on echocardiography of 1266 healthy individuals: the HUNT study in Norway","volume":"11","author":"Dalen","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.ejim.2019.07.022_bb0370","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0375","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2016.12.012","article-title":"A test in context: myocardial strain measured by speckle-tracking echocardiography","volume":"69","author":"Collier","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0380","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0385","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/13506129.2018.1493989","article-title":"Right ventricular involvement in transthyretin amyloidosis","volume":"25","author":"Arvidsson","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.ejim.2019.07.022_bb0395","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1161\/CIRCIMAGING.112.000192","article-title":"Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume","volume":"6","author":"Miller","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0400","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","article-title":"Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2019.07.022_bb0405","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0410","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcmg.2015.10.027","article-title":"LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis","volume":"9","author":"Boynton","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0415","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/joim.12324","article-title":"Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging","volume":"277","author":"Barison","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0420","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0425","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0430","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12968-017-0419-6","article-title":"The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis","volume":"20","author":"Lin","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.ejim.2019.07.022_bb0435","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0440","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2015141744","article-title":"Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study","volume":"277","author":"Fontana","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.ejim.2019.07.022_bb0445","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult Transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0450","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0455","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12968-018-0478-3","article-title":"Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis","volume":"20","author":"Ridouani","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.ejim.2019.07.022_bb0460","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCIMAGING.113.001396","article-title":"How to image cardiac amyloidosis","volume":"7","author":"Falk","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0465","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jcmg.2009.08.008","article-title":"Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis","volume":"2","author":"Austin","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0470","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0475","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cardfail.2017.08.445","article-title":"Myocardial amyloid quantification with look-locker magnetic resonance sequence in cardiac amyloidosis. Diagnostic accuracy in clinical practice and histological validation","volume":"24","author":"Pozo","year":"2018","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2019.07.022_bb0480","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0485","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11886-019-1097-9","article-title":"Molecular imaging of cardiac amyloidosis","volume":"21","author":"Pelletier-Galarneau","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ejim.2019.07.022_bb0490","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","article-title":"Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis","volume":"25","author":"Stats","year":"2016","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0495","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","article-title":"Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis","volume":"4","author":"Rapezzi","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0500","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/13506129.2013.871250","article-title":"Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis","volume":"21","author":"Glaudemans","year":"2014","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0505","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0510","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0515","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","article-title":"Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis","volume":"22","author":"Galat","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0520","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","article-title":"Quantitation of (99m)Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis","volume":"25","author":"Ross","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0525","article-title":"Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis","author":"Sperry","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0530","article-title":"Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis","author":"Rapezzi","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0535","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11886-018-0970-2","article-title":"Clinical phenotyping of transthyretin cardiac amyloidosis with bone-seeking radiotracers in heart failure with preserved ejection fraction","volume":"20","author":"Chen","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ejim.2019.07.022_bb0540","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s12350-017-1141-3","article-title":"Cardiac ATTR amyloid nuclear imaging-not all bone scintigraphy radionuclide tracers are created equal","volume":"25","author":"Yang","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0545","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0550","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0555","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12350-016-0707-9","article-title":"Early-phase myocardial uptake intensity of (99m)Tc-HMDP vs (99m)Tc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis","volume":"25","author":"Abulizi","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0560","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0565","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.ejim.2019.07.022_bb0570","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0575","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ehjci\/jeu158","article-title":"The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease","volume":"15","author":"Di Bella","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2019.07.022_bb0580","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2019.07.022_bb0585","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0590","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0595","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2019.07.022_bb0600","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0605","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0610","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2019.07.022_bb0615","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejim.2019.07.022_bb0620","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0625","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.ejim.2019.07.022_bb0630","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-019-09804-2","article-title":"Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target","author":"Manolis","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2019.07.022_bb0635","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ejim.2019.07.022_bb0640","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0645","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ejim.2019.07.022_bb0650","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0655","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2019.07.022_bb0660","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ejim.2019.07.022_bb0665","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/CIRCULATIONAHA.118.037593","article-title":"Targeted therapeutics for transthyretin cardiac amyloidosis","volume":"139","author":"Shah","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2019.07.022_bb0670","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ajt.13025","article-title":"Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era","volume":"15","author":"Davis","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ejim.2019.07.022_bb0675","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.healun.2014.09.006","article-title":"Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy","volume":"34","author":"Davis","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ejim.2019.07.022_bb0680","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/eurjhf\/hfp121","article-title":"Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis","volume":"11","author":"Kristen","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2019.07.022_bb0685","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","article-title":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","volume":"37","author":"Kristen","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ejim.2019.07.022_bb0690","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10741-017-9601-z","article-title":"Heart transplantation in cardiac amyloidosis","volume":"22","author":"Sousa","year":"2017","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2019.07.022_bb0695","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.ejim.2019.07.022_bb0700","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","author":"Emdin","year":"2019","journal-title":"Eur. Heart J."}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519302559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620519302559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:30:08Z","timestamp":1760607008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620519302559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":140,"alternative-id":["S0953620519302559"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2019.07.022","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac amyloidosis: An underdiagnosed\/underappreciated disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2019.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}